Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481959 | 1.00 | P2RX7 (0.39) | P2RX7HTR2CEPHX2GAAHTT | |
| SCHEMBL13627341 | 1.00 | P2RX7 (0.39) | P2RX7HTR2CEPHX2GAAHTT | |
| SCHEMBL4477909 | 0.88 | P2RX7 (0.38) | P2RX7HTR2CEPHX2HTT | |
| SCHEMBL4480936 | 0.88 | P2RX7 (0.38) | P2RX7HTR2CEPHX2HTT | |
| SCHEMBL13627347 | 0.88 | P2RX7 (0.38) | P2RX7HTR2CEPHX2HTT | |
| SCHEMBL4489439 | 0.83 | HTR2C (0.38) | HTR2C | |
| SCHEMBL13627333 | 0.83 | HTR2C (0.38) | HTR2C | |
| SCHEMBL4492625 | 0.81 | CHRNB2 (0.40) | HTR2CGAAHTT | |
| SCHEMBL13627337 | 0.81 | CHRNB2 (0.40) | HTR2CGAAHTT | |
| SCHEMBL13627340 | 0.79 | GAA (0.38) | P2RX7HTR2CEPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773833-A4 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | claimed |
| EP-1773833-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006019940-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | HTR3B, HTR2C, HTR2B | P2RX7 168/4885HTR2C 2/4885EPHX2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.